Jun 26, 2025 | Disease Area Trends
Health and wellness are pivotal for leading a wholesome life. Good health is a blessing. Time and health are the two most precious assets for human beings. Good health provides better possibilities for us to overcome challenges in life and reap its benefits. Do you...
Jun 23, 2025 | Business, Data Analytics, Diabetes, Disease Area Trends
Merck’s two blockbuster diabetes products, Janumet® and Januvia®, are DPP-4 inhibitors that generated nearly $3.3 billion in Sales in 2016.3 Januvia® is especially known for its great cardiovascular safety profile, which has helped differentiate itself in its class....
Jun 23, 2025 | Chronic Disease, Diabetes, Disease Area Trends, Heart Disease
When it comes to improving the lives of patients with chronic illnesses like type-2 diabetes and heart disease, the pharmaceutical industry is playing an ever smaller role. New blockbuster drugs are the lifeblood of pharmaceutical companies. Traditionally, they...
Jun 23, 2025 | Chronic Disease, Diabetes, Disease Area Trends
Novo Nordisk remains a top player in the Diabetes market with blockbuster insulins NovoLog® and Levemir® which brought in a combined almost $3.5 billion in 20166, Victoza® a GLP-1 that brought in $2.1 billion in 20166, and recently launched Basal insulin/GLP-1...
Jun 23, 2025 | COVID-19, Disease Area Trends
Here is a quick update on the ever-evolving world of COVID-19 trials. Since our initial posting on this topic three weeks ago, the number of trials has grown from 100 to over 300. The number of clinical facilities with clinical trials for COVID-19 has grown from 160...
Jun 23, 2025 | Business, Chronic Disease, Diabetes, Disease Area Trends
For years, Eli Lilly’s main contributions to the Diabetes market were their insulins: fast-acting analog Humalog® and human insulin Humalin and two premix offerings in analog Humalog® Mix 50/50 and human premix Humalin 75/25. Despite a legacy category, this portfolio...